Profil
Neil Bell worked as a Director of Clinical Research at Teva Pharmaceuticals Ltd. from 2004 to 2012.
He then worked as an Executive Director and Head of Clinical Operations at Daiichi Sankyo Development Ltd. from 2012 to 2016.
From 2017 to 2019, he worked as a Senior Vice President and Head of Clinical Operations at Autolus Therapeutics Plc.
Bell received his undergraduate degree from The University of Liverpool and his graduate degree from the University of St. Andrews.
Anciens postes connus de Neil Bell
| Sociétés | Poste | Fin |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 08/10/2019 |
Daiichi Sankyo Development Ltd.
Daiichi Sankyo Development Ltd. Miscellaneous Commercial ServicesCommercial Services Provides professional and scientific services | Directeur/Membre du Conseil | 01/01/2016 |
Teva Pharmaceuticals Ltd.
Teva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Directeur Technique/Scientifique/R&D | 01/01/2012 |
Formation de Neil Bell
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
The University of Liverpool
The University of Liverpool Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of St. Andrews
University of St. Andrews Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Teva Pharmaceuticals Ltd.
Teva Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Daiichi Sankyo Development Ltd.
Daiichi Sankyo Development Ltd. Miscellaneous Commercial ServicesCommercial Services Provides professional and scientific services | Commercial Services |
Autolus Therapeutics Plc
Autolus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of gene therapies | Health Technology |
















